SENS - Senseonics Holdings, Inc.
NYSE
->
Healthcare
->
Diagnostics & Research
Germantown,
United States
Type: Equity
SENS price evolution
SENS
| (in millions $) | 30 Oct 2024 | 30 Jul 2024 | 1 May 2024 | 31 Jan 2024 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | $2.76 | |||
| Short term investments | ||||
| Net receivables | $6.6 | |||
| Inventory | $8.78 | |||
| Total current assets | $130.03 | |||
| Long term investments | ||||
| Property, plant & equipment | $6.36 | |||
| Goodwill & intangible assets | ||||
| Total noncurrent assets | ||||
| Total investments | ||||
| Total assets | $138.22 | |||
| Current liabilities | ||||
| Accounts payable | $4.57 | |||
| Deferred revenue | ||||
| Short long term debt | ||||
| Total current liabilities | $17.26 | |||
| Long term debt | $41.2 | |||
| Total noncurrent liabilities | ||||
| Total debt | ||||
| Total liabilities | $64.77 | |||
| Shareholders' equity | ||||
| Retained earnings | -$869.26 | |||
| Other shareholder equity | -$0.01 | |||
| Total shareholder equity | ||||
| (in millions $) | 31 Jan 2024 | 31 Jan 2023 | 31 Jan 2022 | 30 Jan 2021 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | $2.76 | $1.14 | $4.26 | $18.2 |
| Short term investments | ||||
| Net receivables | $6.6 | $2.79 | $2.42 | $2.99 |
| Inventory | $8.78 | $7.31 | $6.32 | $5.28 |
| Total current assets | $130.03 | $161.2 | $144.41 | $30.25 |
| Long term investments | ||||
| Property, plant & equipment | $6.36 | $4.14 | $1.31 | $1.56 |
| Goodwill & intangible assets | ||||
| Total noncurrent assets | $5.67 | |||
| Total investments | ||||
| Total assets | $138.22 | $177.67 | $198.93 | $35.92 |
| Current liabilities | ||||
| Accounts payable | $4.57 | $0.42 | $1.2 | $1.76 |
| Deferred revenue | ||||
| Short long term debt | ||||
| Total current liabilities | $17.26 | $31.47 | $18.39 | $16.64 |
| Long term debt | $41.2 | $56.38 | $59.8 | $57.22 |
| Total noncurrent liabilities | $160.55 | |||
| Total debt | ||||
| Total liabilities | $64.77 | $142.59 | $384.46 | $177.19 |
| Shareholders' equity | ||||
| Retained earnings | -$869.26 | -$808.87 | -$950.99 | -$648.51 |
| Other shareholder equity | -$0.01 | -$0.68 | -$0.21 | |
| Total shareholder equity | ||||
| (in millions $) | 30 Oct 2024 | 30 Jul 2024 | 1 May 2024 | 31 Jan 2024 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | $4.26 | $4.87 | $5.05 | $8.03 |
| Cost of revenue | ||||
| Gross Profit | -$4.05 | $0.3 | $0.34 | $1.09 |
| Operating activities | ||||
| Research & development | ||||
| Selling, general & administrative | ||||
| Total operating expenses | $18.8 | $19.79 | $18.57 | $18.09 |
| Operating income | ||||
| Income from continuing operations | ||||
| EBIT | ||||
| Income tax expense | ||||
| Interest expense | -$1.12 | -$0.79 | -$0.66 | -$0.19 |
| Net income | ||||
| Net income | -$23.98 | -$20.29 | -$18.88 | -$17.19 |
| Income (for common shares) | ||||
| (in millions $) | 31 Jan 2024 | 31 Jan 2023 | 31 Jan 2022 | 30 Jan 2021 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | $22.39 | $16.39 | $4.95 | |
| Cost of revenue | ||||
| Gross Profit | $3.09 | $2.73 | -$17.37 | |
| Operating activities | ||||
| Research & development | ||||
| Selling, general & administrative | ||||
| Total operating expenses | $78.69 | $71.35 | $62.08 | |
| Operating income | -$79.13 | |||
| Income from continuing operations | ||||
| EBIT | ||||
| Income tax expense | ||||
| Interest expense | $15.01 | $211.09 | $16.17 | |
| Net income | ||||
| Net income | -$60.39 | $142.12 | -$175.17 | |
| Income (for common shares) | ||||
| (in millions $) | 30 Oct 2024 | 30 Jul 2024 | 1 May 2024 | 31 Jan 2024 |
|---|---|---|---|---|
| Net income | ||||
| Operating activities | ||||
| Depreciation | ||||
| Business acquisitions & disposals | ||||
| Stock-based compensation | ||||
| Total cash flows from operations | ||||
| Investing activities | ||||
| Capital expenditures | ||||
| Investments | ||||
| Total cash flows from investing | -$14.83 | -$18.15 | $25.38 | $89.71 |
| Financing activities | ||||
| Dividends paid | ||||
| Sale and purchase of stock | ||||
| Net borrowings | ||||
| Total cash flows from financing | $12.76 | $9.02 | $10.03 | $20.37 |
| Effect of exchange rate | ||||
| Change in cash and equivalents | -$48.29 | -$40.54 | $15.15 | $39.92 |
| (in millions $) | 31 Jan 2024 | 31 Jan 2023 | 31 Jan 2022 | 30 Jan 2021 |
|---|---|---|---|---|
| Net income | -$175.17 | |||
| Operating activities | ||||
| Depreciation | ||||
| Business acquisitions & disposals | ||||
| Stock-based compensation | ||||
| Total cash flows from operations | -$67.42 | |||
| Investing activities | ||||
| Capital expenditures | ||||
| Investments | ||||
| Total cash flows from investing | $89.71 | $26.88 | -$148.75 | -$0.18 |
| Financing activities | ||||
| Dividends paid | ||||
| Sale and purchase of stock | ||||
| Net borrowings | ||||
| Total cash flows from financing | $20.37 | $41.76 | $220.08 | -$10.13 |
| Effect of exchange rate | ||||
| Change in cash and equivalents | $39.92 | $2.33 | $15.25 | -$77.73 |
News
Fundamentals
| Market cap | N/A |
|---|---|
| Enterprise value | N/A |
| Shares outstanding | N/A |
| Revenue | $22.20M |
|---|---|
| EBITDA | N/A |
| EBIT | N/A |
| Net Income | -$80.33M |
| Revenue Q/Q | -7.77% |
| Revenue Y/Y | N/A |
| P/E ratio | N/A |
|---|---|
| EV/Sales | N/A |
| EV/EBITDA | N/A |
| EV/EBIT | N/A |
| P/S ratio | N/A |
| P/B ratio | N/A |
| Book/Share | N/A |
| Cash/Share | N/A |
| EPS | N/A |
|---|---|
| ROA | N/A |
| ROE | N/A |
| Debt/Equity | N/A |
|---|---|
| Net debt/EBITDA | N/A |
| Current ratio | N/A |
| Quick ratio | N/A |